Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482949 · ClinicalTrials.gov registry record · Phase 2
A Rollover Protocol for Subjects Previously Treated With AGS-003
A Phase 2 study, sponsored by Argos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01482949 is a Phase 2 study that was terminated before completion, run by Argos Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT01482949, a Phase 2 study, was terminated before completion, sponsored by Argos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.
Interventions
- DRUG AGS-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482949
The ClinicalTrials.gov registry entry for NCT01482949 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGS-003 is the first listed.
NCT01482949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482949 about?
NCT01482949 is a clinical study titled "A Rollover Protocol for Subjects Previously Treated With AGS-003". The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.
What is the current status of trial NCT01482949?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-09. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01482949?
The interventions under investigation include: AGS-003 (DRUG).
Who is sponsoring clinical trial NCT01482949?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.